Anemia In Chronic Kidney Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Anemia In Chronic Kidney Disease Market Outlook

Thelansis’s “Anemia In Chronic Kidney Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anemia In Chronic Kidney Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Anemia In Chronic Kidney Disease Overview

Anemia in Chronic Kidney Disease (CKD) is a prevalent condition, particularly in advanced stages, with a frequency exceeding 50% in patients at stages 4 and 5, and often manifesting earlier in individuals with diabetes mellitus (DM). It is characterized as normocytic normochromic, hyperproliferative anemia, contributing significantly to poor outcomes and increased mortality in CKD. The primary cause is the diminished renal production of erythropoietin (EPO), the hormone vital for red blood cell production. Patients with CKD experience elevated iron losses attributed to uremia-associated platelet dysfunction, frequent phlebotomy, and blood entrapment during dialysis, resulting in annual iron losses estimated at 1–3 g in hemodialysis patients. Diagnostic tests for CKD-related anemia include complete blood count (CBC) with differential, peripheral smear, iron indices (iron, ferritin, total iron binding capacity, transferrin saturation), as well as assessments of iron, vitamin B, and folate levels to exclude other reversible causes. Thyroid function tests are also conducted to rule out alternate etiologies. Treatment aims to stimulate red blood cell production and potentially enhance renal function. Erythropoiesis-stimulating agents (ESAs) and iron supplements are the preferred therapeutic modalities. Recombinant human erythropoietin and darbepoetin alfa are commonly used ESAs. The U.S. Food and Drug Administration (FDA) recently approved Jesduvroq tablets (daprodustat) as the first oral treatment for CKD-related anemia in adults undergoing dialysis for at least four months, offering a promising alternative to injectable therapies. However, long-term ESA use carries risks, including hypertension, vasoconstriction, and seizures, necessitating careful monitoring and management during treatment.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: